Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

NPJ Precis Oncol · 2026 · PMC13314944 · PMID 42374111

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

did not reach statistical significancep = 0.2not close (p > 0.1)

40 months for platinum vs targeted therapy, HR 2, 95% CI 0.7–5.9) although this trend did not reach statistical significance ( p = 0.2; Fig. 4B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.